Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?-Reference-Cited by-同舟云学术

Humoral SARS-COV-2 IgG decay within 6 months in COVID-19 healthy vaccinees: The need for a booster vaccine dose?

Published:2021-12 Issue: Volume:94 Page:105-107
ISSN:0953-6205
Container-title:European Journal of Internal Medicine
language:en
Short-container-title:European Journal of Internal Medicine

Author:

Achiron Anat,Mandel Mathilda,Dreyer-Alster Sapir,Harari Gil,Gurevich Michael

Publisher

Elsevier BV

Subject

Internal Medicine

Reference9 articles.

1. BNT162b vaccines are immunogenic and protect non-human primates against SARS-CoV-2;Vogel;bioRxiv,2020

2. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine;Polack;N Engl J Med,2020

3. COVID-19 Infection Survey team. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom;Wei;Nat Microbiol,2021

4. Evolution of Anti-SARS-CoV-2 IgG Antibody and IgG Avidity Post Pfizer and Moderna mRNA Vaccinations;Bliden;medRxiv,2021

5. Seasonal coronavirus protective immunity is short-lasting;Edridge;Nat Med,2020

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects;International Journal of Infectious Diseases;2024-01

2. Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases;European Journal of Internal Medicine;2023-07

3. Clinical pearls and pitfalls of SARS-CoV-2 serology;European Journal of Internal Medicine;2023-05

4. In-depth characterization of long-term humoral and cellular immune responses to COVID-19m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab;Multiple Sclerosis and Related Disorders;2023-04

5. Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies;Multiple Sclerosis and Related Disorders;2022-12